Jakafi Side Effects: What Patients Should Know
Jakafi (ruxolitinib) can cause a range of side effects. The most common ones reported include diarrhea, constipation, nausea, vomiting, and abdominal pain [1]. Patients may also experience fatigue, rash, and headache [1]. Some individuals have reported muscle spasms, bone pain, and dizziness [1].
What Are the Serious Risks Associated with Jakafi?
More serious side effects can occur. These include serious infections, such as pneumonia and sepsis [2]. Patients might develop blood clots, particularly in the lungs or veins, which can be life-threatening [2]. There is also a risk of changes in blood cell counts, leading to low platelet counts (thrombocytopenia), low red blood cell counts (anemia), and low white blood cell counts (neutropenia) [2]. These changes can increase the risk of bleeding, infection, and fatigue [2].
Jakafi can also increase the risk of certain cancers, including skin cancers and non-Hodgkin lymphoma [2]. In some patients, Jakafi has been associated with changes in cholesterol levels [2]. Heart problems, such as heart attack and heart failure, have also been reported [2].
What Happens if I Miss a Dose of Jakafi?
If a dose of Jakafi is missed, it should be taken as soon as the patient remembers, unless it is already close to the time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule should be resumed. Patients should not take a double dose to make up for a missed one [3].
How Does Jakafi Work?
Jakafi is a Janus kinase (JAK) inhibitor, specifically targeting JAK1 and JAK2 enzymes [4]. These enzymes play a role in signaling pathways that are involved in inflammation and the growth of certain blood cells [4]. By inhibiting these enzymes, Jakafi helps to reduce the overproduction of abnormal cells and inflammation associated with myeloproliferative neoplasms [4].
When Does Jakafi Patent Protection End?
Information on the specific patent expiry dates for Jakafi is available through resources like DrugPatentWatch.com [5]. This site tracks patent filings and expiry for pharmaceutical drugs, offering insights into when generic competition might emerge.
Are There Alternatives to Jakafi for Myelofibrosis?
Alternative treatments for myelofibrosis exist, depending on the patient's specific condition and disease stage. These may include other JAK inhibitors, or therapies aimed at managing symptoms and complications [6]. For certain patients, stem cell transplantation might be an option [6].
What Clinical Trials Have Been Conducted for Jakafi?
Numerous clinical trials have evaluated the efficacy and safety of Jakafi in various myeloproliferative neoplasms, including myelofibrosis and polycythemia vera [7]. These trials have contributed to understanding its benefits in reducing spleen size, improving symptoms, and prolonging survival in eligible patients [7]. Data from these trials inform prescribing information and ongoing research [7].
How Much Does Jakafi Cost?
The cost of Jakafi can vary significantly based on insurance coverage, dosage, and geographic location. Pharmaceutical assistance programs may be available to help eligible patients with the cost of treatment [8].
Sources:
1. https://www.drugs.com/sfx/jakafi-side-effects.html
2. https://www.rxlist.com/jakafi-side-effects-drug-center.htm
3. https://www.ucsfhealth.org/medications/jakafi
4. https://www.cancer.gov/publications/dictionaries/cancer-drug/def/ruxolitinib
5. https://drugpatentwatch.com/
6. https://www.mayoclinic.org/diseases-conditions/myelofibrosis/diagnosis-treatment/drc-20354532
7. https://www.clinicaltrials.gov/ct2/results?recr=Active&cond=Myelofibrosis&term=ruxolitinib
8. https://www.patientassistance.com/drug/jakafi/